Introduction
Cellular senescence, also known as irreversible terminal growth arrest has recently garnered considerable attention as an anticancer mechanism. Although apoptosis or programmed cell death is an important mechanism leading to tumor regression and a key indicator of the effectiveness of chemotherapy treatment, resistance to cell death pathways generally activated by chemotherapies is a common occurrence (1) . Therefore, cellular senescence is an alternate mechanism sharing only some components of the drug-induced apoptotic pathway that may be exploited to achieve better chemosensitivity leading to tumor suppression. Whether cells respond with apoptosis or cellular senescence may rely on a number of factors including the drug itself, its concentration and mechanisms of action (2, 3) . It is characterized by morphological changes in cells, including increased size and vacuole formation in cytoplasm (4); biochemical changes such as the presence of senescence-associated b-galactosidase (SA-b-gal), lack of DNA synthesis and increased expression of p16 INK4A , p53, p21 CIP1 , ataxia telangiectasia mutated (ATM) and plasminogen activator inhibitor proteins (PAISERP1 and 2) (5, 6) .
A number of mechanisms can lead to cellular senescence in cancer cells. The progressive shortening of telomeres due to inactivation of DNA-repair mechanisms such as telomerase can lead to insufficiently short end sequences halting DNA replication and activating cell cycle arrest (7) . This DNA damage response is mediated through ATM and CHK2. As well, oncogenes in members of the RAS and E2F1 signaling pathways can cause cells to senesce when overexpressed (8, 9) . Often a requirement of senescence is the mutation of p16 and p53, which are key tumor suppressors that may control the initiation of cellular senescence. Antiproliferative cytokines such as interferon-b can increase intracellular oxygen radicals that lead to DNA damage-induced senescence (10) . DNA damaging chemotherapies have especially been noted to induce cellular senescence in cancers. Topoisomerase inhibitors, such as camptothecin (CPT), induce DNA damage in CRC cells, HCT116, by disrupting DNA replication machinery causing cells to either senesce or undergo apoptosis (2) . Cisplatin, 5-fluorouracil (5FU) and doxorubicin, all of which can lead to severe DNA damage, can also induce senescence in head, neck and prostate cancers, respectively (11, 12) .
Studies have shown that induced premature senescence involves either a p53-or p16-dependent pathway (13) . For example, exposure of lung and breast cancers to chemotherapy causes DNA damage raising ATM and CHK2 levels, which lead to downstream p53-mediated activation of p21 (14, 15) . p21 then inhibits CDK4 and CDK2 phosphorylation of retinoblastoma (Rb), preventing E2F3 expression thereby leading to cell cycle arrest and cellular senescence (16) . Similarly, p16 inhibits CDK4 and CDK6 preventing phosphorylation of Rb also leading to cell cycle arrest (17) . Activation of p16 in response to DNA damage is not clearly understood but has been implicated to involve transcription of the INK4A locus which may be regulated by Ets transcription factors, inhibitor of DNA binding (ID1) and B lymphoma Mo-MLV insertion region (BMI1) (18, 19) . Evidence of an interplay between p53 and p16 pathways is unclear; however, some have observed that both tumor suppressors may have roles in a multistage or a parallel mechanistic onset of senescence (20, 21) . The role of cellular senescence as a possible anticancer mechanism is highlighted by (i) the common occurrence of p53 or p16 silencing, bypassing senescent pathways in breast cancer cells (22) , (ii) the presence of senescent cells in benign but not malignant tumors and (iii) evidence that lymphomas can engage in a p53/p16 INK4A -dependent drug-induced senescence which leads to better prognosis (23) .
Our interest in drug-induced cellular senescence was triggered by recent observations that the matricellular protein, secreted protein acidic and rich in cysteine (SPARC), is involved in chemosensitivity (24, 25) and is associated with improved prognosis in ovarian cancer (26) . As well, we have previously discovered that resistant CRCs have lower levels of SPARC relative to sensitive CRCs (24) . Since SPARC is also known to interfere with cell proliferation and cell cycle progression (27) , we hypothesize that it may also be involved in promoting cellular senescence following exposure to low concentrations of chemotherapy. In this study, we investigated the role of cellular senescence with respect to chemotherapy in both resistant and sensitive CRCs and showed that low doses of CPT-11 were sufficient in producing a senescent response both in vitro and in vivo. Furthermore, we showed that SPARC could increase the effect of CPT-11 in inducing cellular senescence most strikingly in resistant CRCs. This effect appeared to be mediated by a p16-and p53-dependent pathway.
(Invitrogen). Resistant cells MIP/5FU, MIP/CPT and RKO/CPT were supplemented with 50 lM 5FU or 5 lM CPT-11, respectively.
Cell synchronization
Cells were synchronized to G 1 /S phase using a double thymidine block before all in vitro experiments. Cells were blocked for 16 h using blocking solution (2 mM thymidine, 2% NCS in DMEM), released for 14 h with DMEM supplemented with 10% NCS and 1% penicillin-streptomycin and 1% kanamycin (Invitrogen) followed by a second 16 h block.
SA-b-gal assay
Cells were seeded at 10 000-12 000 cells in a 48-well plate for 24 h. Following cell cycle synchronization, cells were treated with 0-20 lM 5-FU or 2-20 lM CPT-11 and 0-10 ng/ml recombinant SPARC protein (rSPARC; kind gifts from Dr Neil Desai; Abraxis Bioscience LLC, Los Angeles, CA). The activity of rSPARC was confirmed based on its known interaction with procaspase-8 to enhance apoptosis (25) . Cells were washed in phosphatebuffered saline 2Â and fixed in 2% formaldehyde and 0.2% glutaraldehyde solution for 15 min at room temperature. Following two washes with phosphate-buffered saline, cells were stained with SA-b-gal staining solution [1 mg of 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside in dimethylformamide (X-gal), 40 mM citric acid, 40 mM sodium phosphate, 150 mM NaCl, 2 mM MgCl 2 , 5 mM potassium ferrocyanide and 5 mM potassium ferricyanide, pH 6 .0] at 37°C in a humidified chamber for 24 h (5). The percentage of senescent cells, characterized by an intracellular blue insoluble precipitate inside the cell, was visually determined by the total number of positive cells divided by the total cell number. Cells were visualized under Â40 magnification using a Zeiss light microscope and Canon EOS digital camera for image capturing. Four fields of $100 cells were counted and each experiment was repeated three times.
Cell proliferation, immunoblotting, assessment of apoptosis and reverse transcription-polymerase chain reaction Please refer to supplementary Materials and Methods (S-methods) for details.
RNA interference
To optimize the conditions for effective knock down of p16 INK4A and p53 gene expression with small interfering RNA (siRNA), MIP, MIP/SP and MIP/CPT cells were seeded (six-well plate). Twenty-four hours later, cells were transiently transfected with 20-40 nM of either scramble oligonucleotide sequence (control) or pairs of p16 INK4A or p53 siRNA (Stealth RNAi; QIAGEN, Valencia, CA) for 72 h using HiPerfect transfection reagent (QIAGEN). Reverse transcriptionpolymerase chain reaction analysis described above showed that 40 nM of siRNA yielded the most efficient knock down (8-fold decrease for p53 and 13-fold decrease for p16, supplementary Figure D is available at Carcinogenesis Online). For all subsequent experiments, 40 nM of siRNA or scramble control was used, and transient transfections were carried out for at least 72 h. Cells were assessed for cellular senescence using SA-b-gal staining and protein using immunoblotting following p16 INK4A and p53 siRNA transfection.
Transient transfection MIP and MIP/SP cells were seeded at 100 000-150 000 cells per plate on 60 mm plates for 24 h. Following cell cycle synchronization, 0.5 lg of pC53-SN3 vector construct (provided generously by B.Volgelstein (28)), was incubated with 3 lg polyethylenimine (Sigma, St Louis, MO) in DMEM containing 10% NCS for 2 h and then with complete medium overnight before the addition of 2 lM CPT-11 for another 2 days.
In vivo studies
Tumor xenografts were harvested from National Institutes of Health nude mice (6 weeks old, Taconic Laboratories, Hudson, NY) injected with 2 Â 10 6 MIP101 and MIP/CPT cells as described previously (24) . The experimental groups in this study (n 5 12 tumors per group, three to four animals per group, each bearing four tumors per animal) included treatment with saline, CPT, SPARC or CPT þ SPARC. Upon reaching a tumor size of 100 mm 3 , animals received 10 lg/kg CPT-11 and 100 lg per mouse rSPARC by intraperitoneal injection three times a week for 3 weeks as described previously (24) . At the completion of the study, tumor xenografts were harvested, embedded in optimum cutting temperature compound, sectioned at 6 lm thick, stained and processed for SA-b-gal staining and immunofluorescence as described previously. Primary antibodies used for immunofluoresence were p16
INK4A antibody (1:25; Applied Biological Materials, Richmond, BC, Canada) and (p)-p53 antibody (1:50; Cell Signaling #9284, Danvers, MA). Immunofluoresence was quantified by determining the percentage of positively to negatively stained regions by measuring pixel density of each color channel using Adobe Photoshop 6.0.
Statistics
Statistical difference between experimental groups was calculated and analyzed using Student's t-test. Statistical significance was defined as P , 0.05.
Results
Low concentrations of CPT-11 induce greater cellular senescence in CRC cells expressing SPARC Our earlier observations that SPARC can increase chemosensitivity by augmenting apoptosis in response to chemotherapy in addition to slowing cell cycle progression led us to speculate whether SPARC may also play a role in chemotherapy-induced senescence in the presence of lower concentrations of chemotherapy (24) . In order to determine whether SPARC expression could contribute to cellular senescence, we began by assessing sensitive CRC cells, MIP101, incubated with low concentrations of both 5-FU and CPT-11. Low concentrations (10-20 lM) of 5-FU had no effect on the proportion of senescent MIP101 cells after a 48 h exposure ( Figure 1A ). Cell cycle analysis revealed that double thymidine-blocked synchronized cells were completely found in G 1 and S phases,whereas $25% of unsynchronized cells were also found in G 2 phase (supplementary Figure C is available at Carcinogenesis Online). Since senescence is a cell cycle-dependent mechanism, we decided to synchronize cells in G 1 /S phase. We observed that immediately following synchronization, nearly no cells had reached senescence as opposed to 40% after 48 h regardless of drug treatment (supplementary Figure A is available at Carcinogenesis Online). Clearly, the cell cycle could influence the observed percent of senescence and therefore, in all subsequent experiments, cells were synchronized to account for this. When MIP101 and RKO cell lines were exposed to 2 lM CPT-11, the percentage of senescent cells increased significantly in MIP101 (50.7 ± 1.8% versus 43.7 ± 1.2%, P 5 0.03) and RKO (16.0 ± 3.1% versus 4.8 ± 1.8%, P 5 0.01) relative to untreated controls ( Figure 1B ). On the other hand, CPT-11-resistant MIP101 (MIP/ CPT) and CPT-11-resistant RKO (RKO/CPT) cells showed no differences in the percent of senescent cells after 2 lM CPT-11 treatment ( Figure 1B ). However, we observed the effect of 2 lM CPT-11 on our MIP101 cells stably overexpressing SPARC (MIP/SP) and surprisingly found a 2-fold increase in the proportion of senescent cells after being exposed to 2 lM CPT-11 (74.7 ± 3.2% versus 37.3 ± 4.5%, P 5 0.002) relative to no treatment ( Figure 1B ). In turn, MIP/SP cells exhibited higher levels of cellular senescence relative to MIP101 (74.4 ± 3.2% versus 50.7 ± 1.8%, P 5 0.003) and drug-resistant MIP/CPT cells (74.4 ± 3.2% versus 27.7 ± 9.0%, P 5 0.007) following synchronization and exposure to 2 lM CPT-11 ( Figure 1C ) which was also 2-fold higher than lower SPARC-expressing cells. Interestingly, resistant CRCs, MIP/CPT and RKO/CPT, shown to have significantly lower expression of SPARC relative to their sensitive counterparts (supplementary Figure B is available at Carcinogenesis Online) also responded the least to CPT-11-induced senescence, thereby supporting our hypothesis that SPARC may positively influence cellular senescence.
Exogenous SPARC is capable of increasing cellular senescence in resistant CRC cells Based on the above results, the proportion of cells undergoing cellular senescence appear to be related to the level of SPARC expression; for example chemotherapy-resistant MIP/CPT known to have very low SPARC expression failed to achieve greater senescence following exposure to low CPT concentrations. However, MIP/SP cells with endogenous expression of SPARC were capable of significantly increasing cellular senescence in response to CPT-11 in a manner that was significantly greater than medium-low SPARC-expressing control MIP101 cells. Since we previously established that MIP/CPT and RKO/CPT cells had lowest SPARC expression (supplementary Figure B is available at Carcinogenesis Online), we decided to test whether they could be triggered to undergo senescence when exposed to exogenous SPARC enhances senescence in colorectal cancer via P53 rSPARC. To test this hypothesis, we incubated MIP/CPT and RKO/ CPT cells with 1-10 ng/ml rSPARC and 2 lM CPT-11 and found that the combination of 10 ng/ml rSPARC with CPT-11 produced a dramatically greater proportion of senescent MIP/CPT (62 ± 2.1% versus 38.7 ± 4.1%, P 5 0.007) and RKO/CPT cells (14.0 ± 1.0% versus 5.0 ± 1.7%, P 5 0.003) compared with non-CPT-and non-SPARC-treated cells (Figure 2A and B) . While MIP/CPT cells seemed to respond to SPARC and CPT in a dose-dependent manner, the increase in senescence of RKO/CPT cells appeared to be more abrupt, by occurring mainly after incubation with 10 ng/ml of SPARC and CPT-11. In these resistant cell lines, senescence increased up to 3-fold higher when exposed to 10 ng/ml of rSPARC, suggesting that the combination of SPARC and CPT-11 is required for chemotherapyinduced senescence in the face of a chemotherapy-resistant phenotype.
To further evaluate these senescent cell populations, we confirmed the absence of BrdU incorporation in these b-gal-positive cells, whereas b-gal-negative cells continued to replicate ( Figure 3A) . Specifically, it was noted that after treatment with 2 lM CPT-11, 27.5 ± 1.7% of cells were b-gal positive. However, 22.0 ± 1.7% of cells that had incorporated BrdU were devoid of b-gal staining, whereas just 1.1 ± 0.3% were both b-gal and BrdU positive. In addition, we also measured PAI-SERP1 and 2 expression in our cell lines exposed to CPT-11 because studies have demonstrated upregulation of these two genes in senescent cells (6, 29) . We found a similar increase in the expression of PAI-SERP1 and 2 when MIP/ZEO and MIP/SP cells were exposed to CPT-11 but interestingly not in MIP/ CPT ( Figure 3B ). In addition, we measured caspase-3/7 levels after 48 h of 2 lM CPT-11 exposure and found no changes in any of the MIP-related cell lines ( Figure 3C ) thereby supporting our observation that 2 lM CPT-11 was insufficient to produce an apoptotic response. These results were further confirmed by terminal deoxynucleotidyl transferase dUTP nick end labeling assay of MIP/SP or resistant MIP/ CPT cells exposed to 2 lM CPT-11 ( Figure 3D ).
p16INK4A is upregulated in cells exposed to SPARC and CPT-11 Thus far, our results show that cells exposed to higher levels of SPARC in combination with low concentrations of CPT-11 are more probably to undergo cellular senescence. Our next goal was to investigate if any gene known to be involved in cellular senescence may also be contributing to this SPARC-induced effect. A number of genes regulate the cell cycle and specifically in response to DNA damage such as members of the p53 and p16 (Figure 4C ), whereas both cell lines also displayed a similar but less dramatic increase in phosphorylation of p53 (serine 15).
Reduction in cellular senescence following knock down of p16INK4A and p53 but the latter only in cells overexpressing SPARC The p53 pathway is a well-known mediator of DNA-damage induced senescence. Both p53 and p16 pathways converge upon Rb phosphorylation leading to cellular senescence. The relative contributions of each pathway depend on a variety of stresses but a parallel model of activation has been suggested (21) . We note that higher levels of p16 INK4A are seen in CRC cells overexpressing SPARC, which is the group of cells most probably to undergo CPT-induced senescence. To elucidate a possible mechanism, we used knock down of p16 INK4A and p53 by siRNA transfection to investigate their effect on senescence. Pairs of p16 INK4A and p53 siRNA were optimized to 40 nM (supplementary Figure D is available at Carcinogenesis Online). Incubation with 2 lM CPT-11 in conjunction with knock down of p16 INK4A resulted in a decrease of cellular senescence across all cell lines: MIP101 by 41.3% (14.7 ± 1.2% versus 25.0 ± 1.3%, P 5 0.0002), MIP/SP by 25.4% (29.3 ± 0.4% versus 39.3 ± 2.1%, P 5 0.0009) and MIP/CPT by 21.9% (20.2 ± 0.5% versus 25.8 ± 2.4%, P 5 0.04) relative to non-specific scramble control. As expected, MIP/CPT cells exposed to rSPARC had a significantly greater proportion of cells undergoing senescence but this effect was also abolished following p16 INK4A knock down. Specifically, MIP/ CPT exposed with 10 ng/ml rSPARC had a reduction in senescent cells by 44.8% (18.7 ± 2.4% versus 33.8 ± 2.0%, P 5 0.001). Only cells treated with both 10 ng/ml rSPARC and 2 lM CPT-11 (black) had significantly increased cellular senescence relative to untreated controls (gray). Cells were synchronized and treated with 1-10 ng/ml rSPARC and 2 lM CPT-11 for 48 h. The percent of senescent cells were counted in three fields after SA-b-gal staining and represent four experimental replicates. Statistical difference, asterisks represents P , 0.05 using Student's t-test. In a different cell line, such as RKO, a reduction of 48.5% (5.7 ± 0.6% versus 11.0 ± 0.9%, P 5 0.002) relative to cells transfected with non-specific scramble control treated with CPT-11 ( Figure 5A ) was also observed with p16 INK4A knock down. Meanwhile, incubation with 2 lM CPT-11 and knock down of p53 reduces the percent of senescent cells only in cells exposed to higher levels of SPARC, either endogenously or exogenously. For example, a decrease by 26.3% (29.0 ± 0.9% versus 39.3 ± 2.1%, P 5 0.0002) was seen in MIP/SP cells whereas rSPARC-treated MIP/CPT cells had a reduction of 22.7% (26.2 ± 2.7% versus 33.8 ± 2.0%, P 5 0.02) relative to cells transfected with non-specific scramble control ( Figure 5B) . Conversely, by introducing overexpression of wild-type p53 in MIP101 cells by transient transfection, the percent of cellular senescence significantly increased but again only in cells overexpressing SPARC (46.6 ± 4.0% versus 31.3 ± 2.6%, P 5 0.03) relative to cells transiently transfected with pcDNA empty vector control ( Figure 5C and D) . Interestingly, in MIP/SP cells, transient transfection of p53 alone significantly increased senescence irrespective of the presence of CPT-11 ( Figure 5D ).
CPT-11 and SPARC are capable of reducing tumor growth associated with elevated cellular senescence in vivo We have established thus far that MIP101 cells respond to CPT-11 and SPARC in vitro with increased cellular senescence. Next, we investigated whether CPT-11 and SPARC would have the same effect on CRCs in vivo. Tumor xenografts of MIP101 and MIP/CPT cells implanted in nude mice and treated for three cycles (three injections a week) of 10 mg/kg CPT-11 and/or 100 lg of SPARC per mouse were examined. Tumors treated with a combination of CPT-11 and SPARC were smaller overall (716.7 ± 185.7 mm 3 versus 240.4 ± 71.8 mm 3 , P 5 0.05 in MIP101 and 573.0 ± 139.6 mm 3 versus 105.9 ± 39.5 mm 3 , P 5 0.003 in MIP/CPT). These same xenografts also harbored a large percentage of cells in senescence by b-gal staining. For example, 67% of xenografts of MIP101 tumors from mice treated with CPT-11 positively stained for b-gal compared with 0% with saline ( Figure 6A ). Amazingly, 100% of xenografts from MIP/CPT tumors from mice that were treated with both CPT-11 and SPARC stained positively for b-gal, compared with just 33% in xenografts from mice with saline treatment ( Figure 6B ). p16 INK4A and phospho-p53 were minimal in xenografts from saline-treated mice, whereas these were elevated in tumor xenografts of mice treated with SPARC and CPT-11 ( Figure 6C and D) . In particular, regions stained positive for SA-b-gal displayed higher levels of both these proteins ( Figure 6 ). Overall, these results reveal a new biological role for SPARC in enhancing the induction of cellular senescence in tumors exposed to low concentrations of CPT-11.
Discussion
Cellular senescence has been repeatedly shown to have a role in cancer cell response to chemotherapies. Low concentrations of the chemotherapy, camptothecin, are able to induce cellular senescence in 
SPARC enhances senescence in colorectal cancer via P53
HCT116 CRC cells (2) . Camptothecin and the analogue CPT-11 are topoisomerase I inhibitors that lead to inhibition of DNA replication and transcription. It is suspected that topoisomerase inhibitors activate the traditional DNA damage response through upregulation of ATM and downstream p53 (30) . Independently, p16 INK4A has also been shown to become quickly upregulated following CPT-11 exposure in vitro and in vivo (31) . Both of these pathways target Rb, preventing the release of E2F transcription factors and initiating cellular senescence. Furthermore, the role of cellular senescence in cancer has been highly suggested to be antitumorigenic. Mice with tumors that are able to enter into drug-induced senescence have significantly longer survival than those with tumors resistant to drug-induced senescence (23) . Finally, studies have shown that cellular senescence may act as a back up mechanism to apoptotic failure by providing the cell with tumor suppressive function (23) . Our previous work has suggested that SPARC can play a role in resensitizing CRCs leading to tumor regression, which has led us to examine the role of cellular senescence in relation to SPARC.
In this study, we first demonstrate that low concentrations of CPT-11 but not 5-FU are capable of inducing cellular senescence in various CRC cell lines (Figure 1) . Interestingly, 5-FU, which causes DNA damage through the incorporation of fluorodeoxyuridine triphosphate into DNA, has been previously found to initiate cellular senescence through a DNA damage response in CRC cells such as HCT116, albeit at significantly higher drug concentrations (.700 lM 5-FU) (32) . Currently, no other studies have investigated the effect of low concentrations of 5-FU on MIP101 cells leading to cellular senescence. Though MIP101 cells did not senesce in response to low concentrations of 5-FU, a range of 2-20 lM CPT-11 was capable of significantly increasing cellular senescence in these cells. While higher concentrations of topoisomerase inhibitors have been known to induce apoptosis, low doses have been noted to result in cellular senescence (2) . In particular, the case of low drug concentrations that are capable of activating cellular senescent mechanisms in CRCs may be especially notable since drug cytotoxicity remains a serious hurdle in the treatment of CRCs.
An important observation made in this study is that although increased cellular senescence is seen in sensitive CRC cell lines following exposure to low concentrations of CPT-11, the response is diminished in chemotherapy-resistant CRCs. We previously showed that resistant CRCs have lower levels of SPARC (24) . However, the presence of SPARC, either endogenously overexpressed or added exogenously reverses resistance to senescence (Figures 1 and 2) . It has been suggested that p53 and p16 INK4A play an independently large role in DNA damage-induced senescence in cancer cells (23) . Our findings show that MIP101 cells exposed to SPARC have increased phospho-p53 and p16 INK4A , which is further increased with the addition of CPT-11 ( Figure 4) . RKO cells show similar increases in p16 INK4A and phospho-p53 levels. Recombinant SPARC alone is able to increase p16 INK4A protein expression in a dose-dependent fashion up to 10 ng/ml. Higher concentrations, such as 100 ng/ml of rSPARC, do not further increase p16 INK4A levels. Interestingly, p16 INK4A appears to be involved specifically with drug-induced senescence since knock down of p16 INK4A alone does not decrease the basal proportion of cells already in senescence. Instead, cellular senescence decreases with p16 INK4A knock down only in the presence of DNA damage, in this case, following exposure to CPT-11 ( Figure 5A ). Normally, p16 INK4A is present in most cells at very low levels; thus, it is interesting that a relationship between SPARC and p16 INK4A was found (33) . Further studies are required to investigate this very interesting relationship.
In addition to p16 INK4A , p53 appears to play a role in drug-induced senescence but surprisingly, only in cells exposed to SPARC as shown by the results obtained following p53 knock down ( Figure 5B ). It is known that cells exhibit increased p53-dependent senescence in response to topoisomerase inhibitors in colon, ovarian and breast carcinoma cell lines (34) . p53 status also dictates the fate of the cell in response to CPT-11 and has been shown to predict response to chemotherapies in various cancers (35, 36) . HCT116 cells bearing wild-type p53 tend to enter into G 1 /S phase arrest, whereas knock down of p53 pushes the cell into apoptosis in response to DNA damage (37) . Finally, p53 phosphorylation is often associated with DNA damage (38) . Higher levels of p53 phosphorylated at serine 15 were observed in MIP101 and RKO cells treated with CPT-11 in the presence of SPARC ( Figure 4C ). There appears to be a relationship between SPARC and sensitivity to p53-dependent senescence. To further support this observation, overexpression of wild-type p53 was capable of increasing cellular senescence only in the presence of endogenously overexpressed SPARC (Figure 5C and D) . This is a novel finding since a direct relationship between SPARC and p53 has not been previously found. Interestingly, the transcription factor v-Jun modulates both p53 and SPARC function. v-Jun has been observed to downregulate SPARC in chick embryo fibroblasts by interfering with its proximal promoter region (39, 40) . Meanwhile, v-Jun has also been shown to stimulate cell cycle progression by reducing p53 transcriptional activity and p21 expression (41) . Nonetheless, the mechanism through which SPARC and p53 may interact would require additional studies.
This study demonstrates a new role for SPARC and its ability to contribute to the induction of cellular senescence. As noted earlier, SPARC has been shown previously to regulate cell cycle progression. In U87 glioma cancer cells, high levels of SPARC were associated with a greater percent of cells in G 0 and G 1 phases (42) . While in CRC cells, a delay in G 1 /S phase has been demonstrated (24) , SPARC has also been noted for its antiproliferative properties in mesangial cells and pancreatic cancer (43, 44) but thus far, there
has not yet been a link between SPARC levels and chemotherapyinduced senescence. In this study, we determine that CRCs overexpressing SPARC have decreased cell viability and lower proliferative rates when treated with low concentrations of CPT-11, but not as a result of apoptosis. Instead, cellular senescence is the mechanism responsible for these observations. Several studies have suggested that senescent cells do not undergo apoptosis in response to DNA damage (45, 46) and that the apoptotic and senescent pathways appear to be exclusive in response to DNA damage (47) . The mechanism deciding a cell's fate toward cellular senescence or apoptosis is not well understood, however, in CRC cells, transcription factor myc has been shown to play a role in deciding the outcome of the p53-dependent DNA damage response (48) . Our results support findings that suggest senescence can serve as a back up mechanism to apoptosis especially in cells displaying some resistance to this cell death mechanism (23) . For example, modulation of Bcl-2 or caspase-3 can cause cells that would normally be induced into apoptosis into senescence instead (46, 49) . While the combination of SPARC and low dose of CPT-11 initiates a tumor repressive response that may not initially clear CRCs and regress tumors, studies have demonstrated clearance of senescent cells by the immune system in mice, therefore, supporting this strategy as an effective mechanism in the treatment of cancer (50) .
Our results are highly clinically relevant because DNA damaging chemotherapies, such as SN-38, a metabolite of CPT-11 and VP-16, have been shown to induce senescence in breast cancers but not normal breast tissue from human patients (34) . We show that treatment of mice with a combination of SPARC and low dose CPT-11 results in greatly increased senescence compared with lone treatment of high dose CPT-11 in chemoresistant tumors. This increase in senescence is correlated with greater p16 INK4A and phospho-p53 ( Figure 6 ). The ability of SPARC to resensitize resistant tumors to cellular senescence suggests that SPARC in combination with standard chemotherapy may indeed be of clinical value. These results are exciting as they shed new insight on a relatively novel anticancer mechanism of SPARC that may be used to exploit cases related to chemotherapy resistance.
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